Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H5K3
UPID:
SG196_HUMAN
Alternative names:
Protein kinase-like protein SgK196; Sugen kinase 196
Alternative UPACC:
Q9H5K3
Background:
Protein O-mannose kinase, also known as Protein kinase-like protein SgK196 or Sugen kinase 196, plays a pivotal role in the post-translational modification of proteins. It specifically phosphorylates the O-mannose of the trisaccharide in alpha-dystroglycan, a process crucial for the binding of extracellular proteins with high affinity. This kinase activity is essential for the structural integrity and function of muscle and brain tissues.
Therapeutic significance:
The protein's involvement in muscular dystrophy-dystroglycanopathy, both congenital with brain and eye anomalies (A12) and limb-girdle (C12), underscores its therapeutic significance. Targeting the pathway or correcting the gene variants affecting Protein O-mannose kinase could lead to innovative treatments for these debilitating disorders.